目的 探討鼻炎康片聯(lián)合盧帕他定治療過敏性鼻炎的臨床療效。方法 選擇2017年2月-2019年3月在成都市新都區(qū)人民醫(yī)院治療的過敏性鼻炎患者73例，隨機分為對照組（36例）和治療組（37例）。對照組晚飯后口服富馬酸盧帕他定片，10 mg/次，1次/d。治療組在對照組的基礎上口服鼻炎康片，4片/次，3次/d。兩組患者均治療14 d。觀察兩組患者臨床療效，同時比較治療前后兩組患者血清白細胞介素-8（IL-8）、IL-6、IL-4和免疫球蛋白E（IgE）水平，及臨床癥狀改善時間。結果 治療后，對照組臨床有效率為72.22%，顯著低于治療組的94.59%，兩組比較差異具有統(tǒng)計學意義（P<0.05）。治療后，兩組患者IL-8、IL-6、IL-4和IgE等指標均顯著降低（P<0.05），且治療組血清因子水平明顯比對照組低（P<0.05）。治療后，治療組患者臨床癥狀改善時間明顯比對照組早（P<0.05）。結論 鼻炎康片聯(lián)合盧帕他定治療過敏性鼻炎，可明顯抑制患者炎癥反應，改善臨床癥狀，顯著提高治療效果。

Objective To investigate the clinical efficacy of Biyankang Tablets combined with lupatadine in treatment of allergic rhinitis. Methods Patients (73 cases) with allergic rhinitis in Xindu District People's Hospital from February 2017 to March 2019 were randomly divided into control (36 cases) and treatment (37 cases) groups. Patients in the control group were po administered with Rupatadine Fumarate Tablets after dinner, 10 mg/time, once daily. Patients in the treatment group were po administered with Biyankang Tablets on the basis of the control group, 4 tablets/time, three times daily. Patients in two groups were treated for 14 d. After treatment, the clinical efficacy was evaluated, and the serum level of IL-8, IL-6, IL-4, and IgE, and the improvement time of clinical symptom in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the control group was 72.22%, which was significantly lower than 94.59% in the treatment group, and there were differences between two groups (P<0.05). After treatment, the serum level of IL-8, IL-6, IL-4, and IgE in two groups was significantly decreased (P<0.05), and the serum factor level in the treatment group was significantly lower than that in the control group (P<0.05). After treatment, the improvement time of clinical symptom in the treatment group was significantly earlier than that in the control group (P<0.05). Conclusion Biyankang Tablets combined with lupatadine in treatment of allergic rhinitis can significantly inhibit the inflammatory reaction, improve clinical symptoms, and significantly improve the treatment effect.

R987